Target Discovery to Diabetes Therapy—TXNIP From Bench to Bedside With NIDDK
Endocrinology · 24.03.2025 · 166 (5)
DOI: 10.1210/endocr/bqaf055 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, online erschienen am 19.03.2025. Verfasst von Anath Shalev. Beteiligte Einrichtung: Department of Medicine, Comprehensive Diabetes Center and Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, B…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, Human Islet Research Network.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes is the most expensive chronic disease in the United States, with more than $400 billion in annual costs, and it affects more than 38 million Americans. While major advances in drug treatment have been made for type 2 diabetes (T2D) and the often-associated obesity, there are still no approved and effective medications targeting β-cell loss or islet dysfunction, which is one of the major underlying causes of both type 1 diabetes (T1D) and T2D. In addition, there are no oral medications for T1D approved in the United States more than 100 years after the discovery of insulin, and attractive therapeutic targets are only starting to emerge. As we celebrate the 75th anniversary of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), progress is finally being made in this area with NIDDK support. This mini-review follows the discovery of thioredoxin-interacting protein inhibitors as an example of a methodical approach to identify and develop an oral β-cell treatment for T1D. It further discusses how the initial molecular findings were translated into novel clinical treatment approaches that promote the patient's own islet health and β-cell function using drug repurposing as well as new drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Comprehensive Diabetes Center and Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL 35294-2182, USA.
ORCID-Profile: Anath Shalev
Förderung
- NIDDK NIH HHS
- NIH HHS
- Human Islet Research Network
- National Institutes of Health
Zitieren
APA
Shalev, A. (2025). Target Discovery to Diabetes Therapy—TXNIP From Bench to Bedside With NIDDK. Endocrinology, 166(5). https://doi.org/10.1210/endocr/bqaf055
Vancouver
Shalev A. Target Discovery to Diabetes Therapy—TXNIP From Bench to Bedside With NIDDK. Endocrinology. 2025;166(5). doi:10.1210/endocr/bqaf055
BibTeX
@article{Shalev2025,
author = {Shalev, Anath},
title = {Target Discovery to Diabetes Therapy—TXNIP From Bench to Bedside With NIDDK},
journal = {Endocrinology},
year = {2025},
volume = {166},
number = {5},
doi = {10.1210/endocr/bqaf055}
}
EUVIMED